SANTA MONICA, Calif.– GoodRx (Nasdaq: GDRX) announced a new collaboration with Novo Nordisk that makes all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month through GoodRx. The initiative, effective immediately, marks the first time Ozempic has been offered at this self-pay price in the U.S.
The partnership expands access to two of the most in-demand GLP-1 medications, which are widely prescribed for type 2 diabetes and obesity but often come with high out-of-pocket costs or limited insurance coverage. GoodRx said the new pricing significantly lowers costs for patients who have struggled to access these treatments.
“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” said Wendy Barnes, president and CEO of GoodRx. “By partnering with Novo Nordisk, we’re taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It’s a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.”
GoodRx reported that nearly 17 million people sought information or savings on GLP-1 medications on its platform in the past year, up 22 percent from the year prior. The company said this collaboration strengthens its ability to meet that rising demand and ensure patients can access authentic, FDA-approved medications.
“Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,” said Dave Moore, executive vice president of U.S. operations at Novo Nordisk Inc. “This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic self-pay offer for type 2 diabetes patients at an unprecedented price.”
GoodRx noted that around 19 million people currently lack coverage for GLP-1 prescriptions for weight loss. By addressing these gaps, the company said the new program will help accelerate access to therapy and broaden affordability for patients nationwide.
